Larvol Delta - Fruquintinib-Plus-Serplulimab-as-FirstLine-Therapy-for-Metastatic-NonClear-Cell-Renal-Cell-Carcinoma

Hetronifly (serplulimab) - Shanghai Henlius Biotech

Fruzaqla (fruquintinib) - Takeda

http://clinicaltrials.gov/ct2/show/NCT05831891

Sep 17, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Next